Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT03274076 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Systemic Sclerosis
Scleroderma

Interventions

DRUG: Tofacitinib
DRUG: Placebo Oral Tablet

Sponsor

University of Michigan

Collaborators

[object Object]